A Randomized Trial of Strategies Using Darbepoetin Alfa To Avoid Transfusions in CKD.

ABSTRACT:

Background

Exposure to high doses or a high cumulative dose of erythropoiesis-stimulating agents (ESAs) may contribute to cardiovascular events in patients with CKD and anemia. Whether using a low fixed ESA dose versus dosing based on a hemoglobin-based, titration-dose algorithm in such patients might reduce risks associated with high ESA doses and decrease the cumulative exposure-while reducing the need for red blood cell transfusions-is unknown.

Methods

In this phase-3, randomized trial involving 756 adults with stage-3 to -5 CKD and anemia, we evaluated incidence of red blood cell transfusions for participants randomized to receive darbepoetin given as a fixed dose (0.45 µg/kg every 4 weeks) versus administered according to a hemoglobin-based, titration-dose algori

SUBMITTER: Toto R 

PROVIDER: S-EPMC8054895 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature